

NOTICE TO THE BAR

MULTICOUNTY LITIGATION – DESIGNATION OF LITIGATION INVOLVING GLP-1 PRODUCTS CAUSING (1) GASTROINTESTINAL INJURIES AND (2) NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY (NAION) VISION LOSS AS SEPARATE MCLS

A previous Notice to the Bar requested comments on two applications for multicounty litigation (MCL) designation of New Jersey state-court litigation alleging injuries caused by GLP-1 medications (Ozempic®, Wegovy®, Rybelsus®, Trulicity®, Mounjaro®, and Zepbound®). The applications requested that GLP-1 litigation involving (1) gastrointestinal injuries and (2) Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) vision loss be designated as separate and distinct MCLs. This Notice is to advise that the Supreme Court, after considering the two applications and the comments received, has determined to designate the two types of cases as separate and distinct multicounty litigations. The Court has assigned both MCLs to Bergen County for centralized case management by Superior Court Judge Gregg A. Padovano.

Published with this Notice are the two October 16, 2025 Supreme Court Orders. The Orders will be posted in the Multicounty Litigation Center <https://www.njcourts.gov/attorneys/multicounty-litigation> on the Judiciary’s website (www.njcourts.gov). Judge Padovano’s Initial Case Management Orders also will be posted in the Multicounty Litigation Center.

Questions concerning this matter may be directed to Melissa A. Czartoryski, Chief, Civil Practice Division, Administrative Office of the Courts, Hughes Justice Complex, P. O. Box 981, Trenton, New Jersey 08625-0981; telephone: (609) 815-2900 ext. 54901; e-mail address: Melissa.Czartoryski@njcourts.gov.

/s/ Michael J. Blee

Michael J. Blee, J.A.D.
Acting Administrative Director of the Courts

Dated: November 10, 2025

SUPREME COURT OF NEW JERSEY

On application made pursuant to Rule 4:38A and the Multicounty Litigation Guidelines and Criteria for Designation (Revised) promulgated by Directive #02-19 in accordance with that Rule, it is hereby ORDERED that all pending and future New Jersey state court actions against Novo Nordisk Inc., Eli Lilly and Company, and Lilly USA, LLC, alleging **gastrointestinal injuries** as a result of the use of **glucagon-like peptide-1 receptor agonist prescription medications Ozempic®, Wegovy®, Rybelsus®, Trulicity®, Mounjaro®, and Zepbound™** be designated as multicounty litigation ("MCL") for centralized management purposes; and

It is FURTHER ORDERED that any and all such complaints that have been filed in the various counties and that are under or are awaiting case management and/or discovery shall be transferred from the county of venue to the Superior Court, Law Division, Bergen County, and that, pursuant to N.J. Const., Art. VI, sec. 2, par. 3, the provisions of Rule 4:3-2 governing venue in the Superior Court are supplemented and relaxed so that all future such complaints, no matter where they might be venued, shall be filed in Bergen County; and

It is FURTHER ORDERED that Superior Court Judge Gregg A. Padovano shall oversee management and trial issues for such cases and may, in his discretion, return such cases to the original county of venue for disposition; and

It is FURTHER ORDERED that no Mediator or Special Adjudicator may be appointed in this litigation without the express prior approval of the Chief Justice.

For the Court,

A handwritten signature in blue ink, appearing to be "Shah Raza", written over a faint horizontal line.

Chief Justice

Dated: October 16, 2025